Metaproterenol
Alupent, Prometa (metaproterenol) is a small molecule pharmaceutical. Metaproterenol was first approved as Alupent on 1982-01-01. It is used to treat asthma, bronchial spasm, chronic bronchitis, and pulmonary emphysema in the USA. The pharmaceutical is active against beta-2 adrenergic receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Metaproterenol sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ALUPENT | Boehringer Ingelheim | N-015874 DISCN | 1982-01-01 | 2 products |
| ALUPENT | Boehringer Ingelheim | N-016402 DISCN | 1982-01-01 | 1 products |
| ALUPENT | Boehringer Ingelheim | N-017571 DISCN | 1982-01-01 | 1 products |
| ALUPENT | Boehringer Ingelheim | N-017659 DISCN | 1982-01-01 | 1 products |
| ALUPENT | Boehringer Ingelheim | N-018761 DISCN | 1983-06-30 | 2 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| prenatryl prometa | unapproved drug other | 2021-04-09 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03A: Adrenergics, inhalants
— R03AB: Non-selective beta-adrenoreceptor agonist inhalants
— R03AB03: Orciprenaline
— R03C: Adrenergics for systemic use
— R03CB: Non-selective beta-adrenoreceptor agonists for systemic use
— R03CB03: Orciprenaline
— R03CB53: Orciprenaline, combinations
HCPCS
Code | Description |
|---|---|
| J7667 | Metaproterenol sulfate, inhalation solution, compounded product, concentrated form, per 10 milligrams |
| J7668 | Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, per 10 milligrams |
| J7669 | Metaproterenol sulfate, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per 10 milligrams |
| J7670 | Metaproterenol sulfate, inhalation solution, compounded product, administered through dme, unit dose form, per 10 milligrams |
Clinical
Clinical Trials
22 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | 1 | — | — | 2 |
| Systemic lupus erythematosus | D008180 | EFO_0002690 | M32 | 1 | — | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | 1 | — | — | — | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | — | — | — | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 5 | — | — | — | — | 5 | ||
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | — | — | — | — | 2 |
| Neoplasms | D009369 | C80 | 1 | — | — | — | — | 1 | |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | — | — | — | — | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | 1 | — | — | — | — | 1 | |
| Infections | D007239 | EFO_0000544 | 1 | — | — | — | — | 1 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Cystic fibrosis | D003550 | EFO_0000390 | E84 | 1 | — | — | — | — | 1 |
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
| Pelvic pain | D017699 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | METAPROTERENOL |
| INN | orciprenaline |
| Description | Metaproterenol is a member of phenylethanolamines. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(C)NCC(O)c1cc(O)cc(O)c1 |
Identifiers
| PDB | — |
| CAS-ID | 586-06-1 |
| RxCUI | 7688 |
| ChEMBL ID | CHEMBL776 |
| ChEBI ID | 6792 |
| PubChem CID | 4086 |
| DrugBank | DB00816 |
| UNII ID | 53QOG569E0 (ChemIDplus, GSRS) |
Target
Agency Approved
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB2
Gene synonyms
ADRB2R, B2AR
NCBI Gene ID
Protein name
beta-2 adrenergic receptor
Protein synonyms
adrenergic, beta-2-, receptor, surface, adrenoceptor beta 2 surface, Beta-2 adrenoceptor, Beta-2 adrenoreceptor, catecholamine receptor
Uniprot ID
Mouse ortholog
Adrb2 (11555)
beta-2 adrenergic receptor (Q8BH38)
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,471 documents
View more details
Safety
Black-box Warning
Black-box warning for: Prenatryl prometa
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
342 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more